7月21日，民银资本盘中大幅下跌17.3%，报4.11港元/股，成交额1.26亿港元。
消息面上，同日北京普祺医药港股IPO招股书正式失效，民银资本为该项目联席保荐人之一。此前公司披露年度业绩时指出，利润同比增长197.73%主因证券承销及保荐服务等费类收入大幅增加，保荐项目未能推进或引发市场对其核心业务收入持续性的担忧。此外，近期南向资金连续多日减持该股，主力资金亦呈大幅净流出态势，短期抛压较重。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.